Companies Forum
an opportunity to network and collaborATE
CRDN Companies Forum meetings welcome representatives from pharmaceutical, biotechnology and healthcare companies operating in the rare disease space who are interested in understanding the regulatory environment for orphan medicinal products and working collaboratively on projects.
Meetings are conducted under Chatham House Rules and held three times a year. Content for discussion is agreed amongst the group and high calibre speakers sourced by CRDN. Meetings are a half to full day, informative, relaxed and collaborative and members receive presented slides and minutes of the meeting for future reference.
COMPANIES FORUM MEMBERS INCLUDE:
UPCOMING 2020 MEETINGS
9 October 2020
Rare Disease Clinical Trials in the COVID/post-COVID environment
The discussion will explore decentralised trials, wearable technology, remote monitoring and protecting vulnerable patients
Venue: Virtual platform
Speakers:
Steven Anderson, CSO, Covance Global CRO
Elin Haf-Davies, CEO, Aperito
Senior Regulator for MHRA CliicalTrails Unit tbc
SPRING 2020 MEETING - 6 MAR
Venue: Royal Society of Medicine, London
Speakers: Professor Ron Akehurst, Uni of Sheffield and Sheela Upadhyaya, HST and Topic Selection Specialist. National Institute for Health and Care Excellence
AUTUMN 2019 MEETING - 29 NOV
Venue: Royal Society of Medicine, London
Speakers: Prof Chas Bountra – University of Oxford, Dan Lewi – CATs Foundation, Tess Harris – PKD UK, Allison Watson – Ring20 Research
CAN CRDN’S COMPANIES FORUM 2020 CONNECT THE DOTS?
Read CRDN’s blog exploring how our Companies Forum is seeking to challenge the status quo in orphan therapeutic development and support companies to connect the dots
Pharmaphorum’s George Underwood talks to CRDN Companies Forum lead Dr. Ron Jortner about the biggest challenges facing rare disease pharma, and how the industry can tackle them.
Dive straight into the feedback!Login below and you can start commenting using your own user instantly